Drug news
EU approves Trulicity, a GLP-1 agonist for treatment of Type 2 Diabetes-Eli Lilly
Eli Lilly and Company announced that the European Commission granted marketing authorisation for Trulicity (dulaglutide) solution for injection. Trulicity, a GLP-1 receptor agonist, is a once-weekly, injectable solution designed to improve glycaemic control in adults with Type 2 Diabetes. The medicine comes in a ready-to-use pen with a pre-attached, hidden needle. Trulicity received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) on 25 September 2014.